Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Should You Buy?

Fresenius SE & Co. (OTCMKTS:FSNUY)’s stock price gapped up before the market opened on Monday. The stock had previously closed at $13.0420, but opened at $13.67. Fresenius SE & Co. shares last traded at $13.6810, with a volume of 485 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Citigroup reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research report on Wednesday. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating. According to MarketBeat, Fresenius SE & Co. has an average rating of “Buy”.

Fresenius SE & Co. Price Performance

The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97. The company has a market capitalization of $30.87 billion, a PE ratio of 17.34 and a beta of 0.60. The firm has a 50-day moving average of $12.89 and a 200 day moving average of $12.87.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. As a group, research analysts anticipate that Fresenius SE & Co. will post 1.04 earnings per share for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.